Duloxetine Hcl Capsule, Delayed Release Pellets
Product Images NDC 80425-0086

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine HCl 30mg Cap Qty 30 Ndc 80425 0086

FDA Label Image

Duloxetine HCl 30mg Cap Qty 60 Ndc 80425 0086

Duloxetine HCl 30mg Cap Qty 60 Ndc 80425 0086
This is a prescription drug label for Duloxetine HCLDR 30mg capsules with 260 capsules in the package. The label includes a product code and number, but there is no other useful information available.*
FDA Label Image

Image 2

Image 2
The text appears to be a graph showing the proportion of patients with relapse over time for a placebo group and a group taking Duloxetine Delayed-Release Capsules. It is not possible to provide a useful description without additional context, such as the study or trial this graph is a part of.*
FDA Label Image

Image 4

FDA Label Image

Image 5

FDA Label Image

Image 6

FDA Label Image

Image 8

Image 8
The text describes a graphical representation of the percentage of patients improved after receiving a placebo or Duloxetine Delayed-Release at different doses daily. The data is represented by a line graph displaying the percentage of patients with an improvement in pain from baseline.*
FDA Label Image

Image 9

Image 9
The text shows a graph showing the percentage of patients who improved after taking Duloxetine Delayed-Release 60 mg Once Daily in comparison to placebo. The graph also indicates the percent improvement in pain from baseline.*
FDA Label Image

Image

Image
This appears to be a graph showcasing the proportion of patients with relapse based on the treatment they received - placebo, Dulorine, or Rl Gapeis - over a certain period of days since randomization. The graph shows that whichever treatment was received, the proportion of patients with relapse increases over time.*
FDA Label Image

Image3

Image3
This text is describing a chart or graph that displays the percentage of patients who have experienced improvement, likely in relation to pain. The specific data provided relates to the percentage improvement in pain from a baseline measurement.*
FDA Label Image

Image 10

FDA Label Image
FDA Label Image

Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.